Research progress of the role and mechanism of CD146 in blood brain barrier

doi:10.3969/j.issn.1672-6731.2020.10.002

Abstract

Abstract:

Cell adhesion molecule CD146 belonging to the immune-globulin superfamily member, was initially identified as a melanoma marker. With the development of CD146 research, it was found that CD146 is a neovascularization marker. The CD146 expression is decreased significantly or absent following with the maturation of blood vessels, indicating the critical role of CD146 in the development and maturation of blood vessels. In recent years, numerous studies have reported that CD146 and its soluble form (sCD146) are involved in development and pathological damage of blood brain barrier (BBB). This paper aims to review the role and mechanism of CD146 in BBB. It will be helpful to further explore the potential value of CD146 in various BBB damage-related brain diseases.

Key words: Neural cell adhesion molecules, Blood-brain barrier, Inflammation, Central nervous system, Review

摘要：

细胞黏附分子CD146是免疫球蛋白超家族成员，最初被认为是黑色素瘤标志物，后续研究发现CD146是新生血管标志物，随着血管的成熟，其表达水平显著下降或不表达，提示其在血管发育和成熟中的重要作用。近年大量文献报道CD146及其可溶形式参与血脑屏障发育和病理性损害过程，本文拟对CD146在血脑屏障中的作用及其机制进行概述，有助于深入探寻CD146在多种血脑屏障损害相关颅内疾病中的潜在价值。

关键词: 神经细胞黏附分子类, 血脑屏障, 炎症, 中枢神经系统, 综述

WANG Da-ji, DUAN Hong-xia, NIE Guo-hui, YAN Xi-yun, HAO Hong-jun. Research progress of the role and mechanism of CD146 in blood brain barrier[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(10): 848-852.

王大吉, 段红霞, 聂国辉, 阎锡蕴, 郝洪军. CD146在血脑屏障中的作用及其机制研究进展[J]. 中国现代神经疾病杂志, 2020, 20(10): 848-852.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2020.10.002

https://journal11.magtechjournal.com/cjcnn/EN/Y2020/V20/I10/848

References

[1] Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmüller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113, 000 and a protein with a molecular weight of 76, 000[J]. Cancer Res, 1987, 47:841-845.
[2] Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue[J]. Mod Pathol, 1998, 11:1098-1106.
[3] Zeng P, Li H, Lu PH, Zhou LN, Tang M, Liu CY, Chen MB. Prognostic value of CD146 in solid tumor:a systematic review and Meta-analysis[J]. Sci Rep, 2017, 7:4223.
[4] Bardin N, George F, Mutin M, Brisson C, Horschowski N, Frances V, Lesaule G, Sampol J. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen[J]. Tissue Antigens, 1996, 48:531-539.
[5] Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigen[J]. Cancer Res, 1994, 54:2514-2520.
[6] Wang Z, Xu Q, Zhang N, Du X, Xu G, Yan X. CD146, from a melanoma cell adhesion molecule to a signaling receptor[J]. Signal Transduct Target Ther, 2020, 5:148.
[7] Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, Liu Q, Mann K, Bader BL. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth[J]. Blood, 2003, 102:184-191.
[8] Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, Feng J, Yang D, Yan X. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis[J]. Blood, 2012, 120:2330-2339.
[9] Pariyawathee S, Phattarataratip E, Thongprasom K. CD146 expression in oral lichen planus and oral cancer[J]. Clin Oral Investig, 2020, 24:325-332.
[10] Breuer J, Korpos E, Hannocks MJ, Schneider-Hohendorf T, Song J, Zondler L, Herich S, Flanagan K, Korn T, Zarbock A. Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus[J]. J Neuroinflamm, 2018, 15:236.
[11] Neidhart M, Wehrli R, Bruhlmann P, Michel BA, Gay RE, Gay S. Synovial fluid CD146(MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis[J]. Arthritis Rheum, 1999, 42:622-630.
[12] Tsiolakidou G, Koutroubakis IE, Tzardi M, Kouroumalis EA. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease[J]. Dig Liver Dis, 2008, 40:673-679.
[13] Bardin N, Reumaux D, Geboes K, Colombel JF, Blot-Chabaud M, Sampol J, Duthilleul P, Dignat-George F. Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease[J]. Inflamm Bowel Dis, 2006, 12:16-21.
[14] Boratyńska M, Karbowska A, Klinger M. The effect of hyperuricemia on endothelial biomarkers and renal function in kidney allograft recipients[J]. Transplant Proc, 2010, 42:4074-4077.
[15] Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M. Markers of endothelial cell activation/injury:CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients[J]. Am J Nephrol, 2005, 25:203-210.
[16] Li L, Zhang BR, Zeng XF, Wang X. A pilot study on the significance of leucocyte CD146 expression in vasculitis[J]. Zhonghua Nei Ke Za Zhi, 2006, 45:748-751. [李玲, 张佰茹, 曾小峰, 汪玄. CD146在血管炎患者外周血白细胞表达的意义初探[J]. 中华内科杂志, 2006, 45:748-751.]
[17] Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The blood-brain barrier in psychosis[J]. Lancet Psychiatry, 2018, 5:79-92.
[18] Obermeier B, Verma A, Ransohoff RM. The blood-brain barrier[J]. Handb Clin Neurol, 2016, 133:39-59.
[19] Goasdoué K, Miller SM, Colditz PB, Björkman ST. Review:the blood-brain barrier; protecting the developing fetal brain[J]. Placenta, 2017, 54:111-116.
[20] Bauer H, Traweger A. Tight junctions of the blood-brain barrier:a molecular gatekeeper[J]. CNS Neurol Disord Drug Targets, 2016, 15:1016-1029.
[21] Lochhead JJ, Yang J, Ronaldson PT, Davis TP. Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders[J]. Front Physiol, 2020, 11:914.
[22] Grieb P, Forster RE, Strome D, Goodwin CW, Pape PC.O2 exchange between blood and brain tissues studied with 18O2 indicator-dilution technique[J]. J Appl Physiol, 1985, 58:1929-1941.
[23] Pardridge WM, Eisenberg J, Yang J. Human blood brain barrier insulin receptor[J]. J Neurochem, 1985, 44:1771-1778.
[24] Zhang Y, Pardridge WM. Rapid transferrin efflux from brain to blood across the blood brain barrier[J]. J Neurochem, 2001, 76:1597-1600.
[25] Wrobel JK, Toborek M. Blood-brain barrier remodeling during brain metastasis formation[J]. Mol Med, 2016, 22:32-40.
[26] Lagana P, Soraci L, Gambuzza ME, Mancuso G, Delia SA. Innate immune surveillance in the central nervous system following Legionella pneumophila infection[J]. CNS Neurol Disord Drug Targets, 2017, 16:1080-1089.
[27] Langen UH, Ayloo S, Gu C. Development and cell biology of the blood-brain barrier[J]. Annu Rev Cell Dev Biol, 2019, 35:591-613.
[28] Chen J, Luo Y, Hui H, Cai T, Huang H, Yang F, Feng J, Zhang J, Yan X. CD146 coordinates brain endothelial cell-pericyte communication for blood-brain barrier development[J]. Proc Natl Acad Sci USA, 2017, 114:E7622-7631.
[29] Chen J, Luo Y, Huang H, Wu S, Feng J, Zhang J, Yan X. CD146 is essential for PDGFRbeta-induced pericyte recruitment[J]. Protein Cell, 2018, 9:743-747.
[30] Yang C, Hawkins KE, Doré S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke[J]. Am J Physiol Cell Physiol, 2019, 316:C135-153.
[31] Ueno M, Chiba Y, Matsumoto K, Murakami R, Fujihara R, Kawauchi M, Miyanaka H, Nakagawa T. Blood-brain barrier damage in vascular dementia[J]. Neuropathology, 2016, 36:115-124.
[32] Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction[J]. Nat Med, 2019, 25:270-276.
[33] Stolp HB, Dziegielewska KM. Review:role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases[J]. Neuropath Appl Neurobiol, 2009, 35:132-146.
[34] Ek CJ, Dziegielewska KM, Stolp H, Saunders NR. Functional effectiveness of the blood-brain barrier to small water soluble molecules in developing and adult opossum (Monodelphisdomestica)[J]. J Comp Neurol, 2006, 496:13-26.
[35] Kolbinger F, Huppertz C, Mir A, Padova FD. IL-17A and multiple sclerosis:signaling pathways, producing cells and target cells in the central nervous system[J]. Curr Drug Targets, 2016, 17:1882-1893.
[36] Wagner CA, Roqué PJ, Goverman JM. Pathogenic T cell cytokines in multiple sclerosis[J]. J Exp Med, 2020, 217:e20190460.
[37] Duan H, Xing S, Luo Y, Feng L, Gramaglia I, Zhang Y, Lu D, Zeng Q, Fan K, Feng J, Yang D, Qin Z, Couraud PO, Romero IA, Weksler B, Yan X. Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS[J]. Sci Rep, 2013, 3:1687.
[38] Duan H, Luo Y, Hao H, Feng L, Zhang Y, Lu D, Xing S, Feng J, Yang D, Song L, Yan X. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis[J]. Neuroscience, 2013, 235:16-26.
[39] Wang D, Duan H, Feng J, Xiang J, Feng L, Liu D, Chen X, Jing L, Liu Z, Zhang D, Hao H, Yan X. Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction[J]. Theranostics, 2020, 10:231-246.

Please choose a citation manager

Content to export